LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lipocine Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$1.53−0.03 (-1.92%)
Close on Oct 19, 2026
- Market cap
- $12.57M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.49 (−49.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Lipocine Inc. saw revenue fall 62.7% to $1.57M over the twelve months to Jun 30, 2026.
Revenue
$1.57M
-62.7% vs. a year earlier
Operating income
-$12.57M
TTM Q2 2026
EPS, diluted
-$1.80
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $12.57M
- P/E ratio
- –
- Price to sales
- 8.01
- Price to book
- 0.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.57M
- Net income
- -$11.85M
- EPS, diluted
- -$1.80
- Book value per share
- $2.65
- Diluted shares
- 8M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.57M-62.7% YoY
Operating income
-$12.57M
Net income
-$11.85M
EPS, diluted
-$1.80
Free cash flow
–
Reported periodTrailing twelve months